Results 31 to 40 of about 2,997 (148)

Revealing Airflow–Particle Dynamics in Dry Powder Inhalers

Small, EarlyView.
An integrated framework combining device and formulation characterization, CFD–DEM simulations, and interpretable machine learning is established. This framework reveals how airflow and particle interactions govern powder dispersion across prevailing dry powder inhalers.
Jiale Chen, Ziyi Fan, Qingliang Yang, Yuanyuan Shao, Dongbing Li, Xiaoyang Wei, Xiang Luo, Kaiqi Shi, Gang Yang, Gensheng Yang, Ying Ma, Yuqing Ye, Jesse Zhu   +12 more
wiley   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

British Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD [PDF]

, 2016
Background: Our previous studies suggested that the site of bronchodilation on CT might differ between inhaled β2 agonists and inhaled anticholinergics in COPD.
Kanda, Rie, Ogawa, Emiko, Nakano, Yasutaka, Seto, Ruriko, Konno, Satoshi, Suzuki, Masaru, Ito, Yoichi M., Nishimura, Masaharu, Shimizu, Kaoruko, Makita, Hironi   +9 more
core   +1 more source

A 1% glycopyrronium bromide cream for topical treatment of severe primary axillary hyperhidrosis in adolescents: safety, local tolerability, systemic exposure and efficacy from an open‐label phase II study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Primary axillary hyperhidrosis (PAHH) results from dysregulation of the autonomic nervous system and typically begins during puberty. Treatment options for adolescents remain limited. This open‐label phase II study evaluated the safety, local tolerability, systemic exposure, and efficacy of 1% GPB cream over 8 weeks in
Rolf‐Markus Szeimies, Ana Kilic, Hubert Reich, Birgit Berger, Erik Schulze zur Wiesche, Leonie Litzka, Katharina Schramm, Susanne Heimstaedt‐Muskett, Clarissa Masur   +8 more
wiley   +1 more source

Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies

European Journal of Clinical Investigation, Volume 56, Issue 10, October 2026.
COPD is a heterogeneous disease driven by overlapping neutrophilic and eosinophilic inflammatory pathways. This review highlights the shift from symptom‐based treatment toward phenotype‐ and biomarker‐directed care. Blood eosinophils, FeNO, and IgE predict corticosteroid responsiveness and identify candidates for biologic therapy.
Sasha Raman, Sreya Rahman, Francesca Polverino, Muhammad Adrish   +3 more
wiley   +1 more source

A novel model-based approach for dose determination of glycopyrronium bromide in COPD

BMC Pulmonary Medicine, 2012
Background Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID) glycopyrronium bromide regimens, using a
Arievich Helen, Overend Tim, Renard Didier, Gibbs Michael, Alagappan Vijay, Looby Michael, Banerji Donald   +6 more
doaj   +1 more source

Hair analysis of formoterol as a novel tool to assess long‐term inhalation medication adherence: Data from the TRICOLON trial

British Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 3235-3245, September 2026.
Aim The aim of this paper is to examine inhaled formoterol concentrations in hair and assess the potential of hair analysis as a tool for measuring long‐term adherence, by validation with objective data from digital inhalers. Methods Hair samples and digital inhaler data were collected from patients with COPD in 10 hospitals in the Netherlands as part ...
Liz J. A. Cuperus, A. Mireille A. Wessels, Huib A. M. Kerstjens, Daan J. Touw, Erik W. M. A. Bischoff, Job van der Palen, Arnoud Aldenkamp, Astrid van Huisstede, Folkert Brijker, Stephan Dik, Lidwien Graat‐Verboom, Martijn Goosens, Peter Th. W. van Hal, Jolanda C. Kuijvenhoven, Lisette I. Z. Kunz, Renske van der Meer, Mariette H. A. Scholma‐Bronsema, Job F. M. van Boven, Johannes C. C. M. in't Veen, the TRICOLON study group, Marjo van der Poel, Irini Piso, Marijke Amelink, Anke Rol, Jennifer de Graaf, Petra Hirmann, Fleur van Tour, Elly Jordens, Lydia Alfing, Gerda Lenderink, Truus Rietveld, Jasmijn van Campen, Jantine de Bruijn, Janice van ter Burg, Liselore Baarssmit, Walter van Litsenburg, Len Knoops, Margot Eggermont‐Schilt, Manon de Waard‐Heijligers, Ilonka Paalvast‐Schouten, Mariette Scholma, Sandra Brookman‐Mozes, Inge Paas, Lidwien Verboom, Karin van Mierlo‐Snoeijs   +44 more
wiley   +1 more source

Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease

, 2015
Glycopyrronium bromide is a new long-acting muscarinic antagonist to be used once-daily, which is approved as a bronchodilator for the symptomatic maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD).
Riario Sforza, Gian Galeazzo, RIDOLO, Erminia, Incorvaia, Cristoforo, Riario Sforza, Edoardo   +3 more
core   +1 more source

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study [PDF]

, 2018
Background Two once-daily long-acting muscarinic antagonists (LAMAs) are currently available for the treatment of chronic obstructive pulmonary disease (COPD) – tiotropium and glycopyrronium.
Chen, Hungta, Chapman, Kenneth R, D’Andrea, Peter, D’Urzo, Anthony, Beeh, Kai-Michael, Bateman, Eric D, Overend, Tim, Nutbrown, Robert, Beier, Jutta, Henley, Michelle   +9 more
core   +3 more sources